Madrigal Pharmaceuticals Inc (MDGL)

May 25, 2026

(MDGL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

May 25, 2026

May 25, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews

May 25, 2026

May 22, 2026

Insider Sell: Richard Levy Sells Shares of Madrigal Pharmaceuticals Inc (MDGL) - GuruFocus

May 22, 2026

May 22, 2026

Director Richard Levy of Madrigal (MDGL) sells 5,682 shares under plan - Stock Titan

May 22, 2026

May 22, 2026

[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan

May 22, 2026

May 21, 2026

Madrigal Pharmaceuticals Inc (FRA:YDO1) Stock Price & 30 Year Financial Data - GuruFocus

May 21, 2026

May 21, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 21, 2026

May 21, 2026

Madrigal hires 15 staff, grants 5,308 stock units vesting over 4 years - Stock Titan

May 21, 2026

May 20, 2026

Madrigal to present Rezdiffra data at EASL Congress 2026 - Investing.com UK

May 20, 2026

May 20, 2026

Madrigal to present Rezdiffra data at EASL Congress 2026 By Investing.com - Investing.com South Africa

May 20, 2026

May 20, 2026

Liver disease drug Rezdiffra shows new data on heart risk markers - Stock Titan

May 20, 2026

May 18, 2026

Madrigal (NASDAQ: MDGL) CMO has 844 shares sold automatically for tax withholding - Stock Titan

May 18, 2026

May 18, 2026

Insider sale notice: MDGL (NASDAQ: MDGL) 844 shares via Morgan Stanley - Stock Titan

May 18, 2026

May 18, 2026

Madrigal Pharmaceuticals (MDGL) Investor Outlook: Significant Potential Upside with a 28.77% Gain on the Horizon - DirectorsTalk Interviews

May 18, 2026

May 18, 2026

What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders - Sahm

May 18, 2026

May 17, 2026

Madrigal Pharmaceuticals Issues Equity Awards to 47 New Hires - MyChesCo

May 17, 2026

May 17, 2026

Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm

May 17, 2026

May 15, 2026

Paulson & Co. (MDGL) holds 1.39M shares, representing 6.1% of Madrigal - Stock Titan

May 15, 2026

May 15, 2026

Madrigal Rezdiffra Sales More Than Double in First Quarter - MyChesCo

May 15, 2026

May 15, 2026

Janus Henderson (MDGL) discloses 2,018,647-share stake, 8.8% ownership - Stock Titan

May 15, 2026

May 14, 2026

Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN

May 14, 2026

May 14, 2026

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN

May 14, 2026

May 14, 2026

Madrigal Licenses Arrowhead Drug Candidate for MASH - MyChesCo

May 14, 2026

May 14, 2026

Number of shareholders of Madrigal Pharmaceuticals, Inc. – GETTEX:YDO1 - TradingView

May 14, 2026

May 14, 2026

(MDGL) Risk Channels and Responsive Allocation - Stock Traders Daily

May 14, 2026

May 14, 2026

Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - MSN

May 14, 2026

May 13, 2026

Truist raises Madrigal Pharmaceuticals stock price target on MASH survey By Investing.com - Investing.com India

May 13, 2026

May 13, 2026

MDGL Maintained by Truist Securities -- Price Target Raised to $709 - GuruFocus

May 13, 2026

May 13, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $709.00 Price Target at Truist Financial - MarketBeat

May 13, 2026

May 13, 2026

Truist raises Madrigal Pharmaceuticals stock price target on MASH survey - Investing.com

May 13, 2026

May 12, 2026

HC Wainwright Issues Pessimistic Estimate for MDGL Earnings - MarketBeat

May 12, 2026

May 12, 2026

HC Wainwright & Co. Maintains Madrigal Pharmaceuticals (MDGL) Buy Recommendation - MSN

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 11, 2026

West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal - VISTA.Today

May 11, 2026

May 11, 2026

Madrigal Pharmaceuticals expands MASH pipeline with genetic treatment - Liver Disease News

May 11, 2026

May 11, 2026

Madrigal Pharmaceuticals Q1 2026 Deep Dive: EPS Beats by 20.9%, Revenue Up 127% - AlphaStreet

May 11, 2026

May 11, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Analyzing A 33% Upside Potential - DirectorsTalk Interviews

May 11, 2026

May 10, 2026

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth - Yahoo Finance

May 10, 2026

May 09, 2026

Madrigal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MDGL) 2026-05-09 - Seeking Alpha

May 09, 2026

May 09, 2026

Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo

May 09, 2026

May 08, 2026

Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative - Sahm

May 08, 2026

May 08, 2026

MDGL Maintained by Canaccord Genuity -- Price Target Lowered to $578 - GuruFocus

May 08, 2026

May 08, 2026

Madrigal (MDGL) Reports Strong Q1 Revenue and Positive Market Ou - GuruFocus

May 08, 2026

May 07, 2026

MDGL Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus

May 07, 2026

May 07, 2026

47 new Madrigal hires get stock awards; options priced at $513.72 - Stock Titan

May 07, 2026

May 07, 2026

Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - Sahm

May 07, 2026

May 07, 2026

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance

May 07, 2026

May 07, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript - Insider Monkey

May 07, 2026

May 07, 2026

Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com Australia

May 07, 2026

May 07, 2026

Madrigal: Q1 Earnings Snapshot - theheraldreview.com

May 07, 2026

May 07, 2026

MSN Money - MSN

May 07, 2026

May 06, 2026

Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027 - MSN

May 06, 2026